A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

计划入组 800 人 · 首次发布于 2026 年 9 月 11 日

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

计划入组 60 人 · 首次发布于 2023 年 6 月 28 日

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

计划入组 23 人 · 首次发布于 2022 年 2 月 15 日

Enfortumab vedotin(备思复)

Enfortumab vedotin(Padcev)

Rx

Hertuzumab Vedotin

Enfortumab Vedotin Plus Pembrolizumab Approved in Japan for Urothelial Carcinoma

European Commission Approves PADCEV™ (enfortumab vedotin) Plus KEYTRUDA® (pembrolizumab) for First-Line Advanced Urothelial Cancer

Enfortumab Vedotin Plus Pembrolizumab Reshapes Bladder Cancer Treatment Landscape